Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,561,934
  • Shares Outstanding, K 70,836
  • Annual Sales, $ 76,990 K
  • Annual Income, $ -143,950 K
  • EBIT $ -194 M
  • EBITDA $ -185 M
  • 60-Month Beta 2.20
  • Price/Sales 20.58
  • Price/Cash Flow N/A
  • Price/Book 3.82

Options Overview Details

View History
  • Implied Volatility 108.48% ( +10.96%)
  • Historical Volatility 66.45%
  • IV Percentile 74%
  • IV Rank 53.92%
  • IV High 193.55% on 12/04/23
  • IV Low 8.94% on 03/19/24
  • Put/Call Vol Ratio 0.15
  • Today's Volume 71
  • Volume Avg (30-Day) 94
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 2,293
  • Open Int (30-Day) 1,555

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/24
See More
  • Average Estimate -0.67
  • Number of Estimates 8
  • High Estimate -0.51
  • Low Estimate -0.88
  • Prior Year -0.77
  • Growth Rate Est. (year over year) +12.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.65 +6.78%
on 11/18/24
29.56 -25.41%
on 11/11/24
-3.47 (-13.60%)
since 10/22/24
3-Month
20.65 +6.78%
on 11/18/24
29.56 -25.41%
on 11/11/24
-1.03 (-4.46%)
since 08/22/24
52-Week
5.65 +290.27%
on 11/27/23
29.56 -25.41%
on 11/11/24
+15.83 (+254.50%)
since 11/22/23

Most Recent Stories

More News
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Presents Preclinical Data on NX-5948 and GS-6791 at ACR Convergence 2024

Nurix Therapeutics presented preclinical data on NX-5948 and GS-6791 at ACR Convergence 2024, highlighting their potential in treating inflammatory diseases.Quiver AI SummaryNurix Therapeutics, Inc. has...

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

NRIX : 22.05 (-1.43%)
Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

NRIX : 22.05 (-1.43%)
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

NRIX : 22.05 (-1.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics...

See More

Key Turning Points

3rd Resistance Point 23.36
2nd Resistance Point 22.98
1st Resistance Point 22.51
Last Price 22.05
1st Support Level 21.66
2nd Support Level 21.28
3rd Support Level 20.81

See More

52-Week High 29.56
Last Price 22.05
Fibonacci 61.8% 20.43
Fibonacci 50% 17.60
Fibonacci 38.2% 14.78
52-Week Low 5.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar